How Roche’s HER2 Franchise Is Positioned in August
Roche’s (RHHBY) Herceptin reported revenues of 3.6 billion Swiss francs in the first half compared to 3.5 billion Swiss francs in the first half of 2017, reflecting ~2.0% YoY year-over-year growth at CER (constant exchange rates).